id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-348342-iqq8kmn0	Uyoga, S.	Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors	2020-07-29		.txt	text/plain	3103	198	58	Methods We measured anti-SARS-CoV-2 spike IgG prevalence by ELISA on residual blood donor samples obtained between April 30 and June 16, 2020. National seroprevalence was estimated using Bayesian multilevel regression and post-stratification to account for non-random sampling with respect to age, sex and region, adjusted for assay performance. Based on these data, we defined anti-SARS-CoV-2 IgG seropositivity as an OD ratio >2 and selected the spike ELISA for this study; the sensitivity and specificity of this threshold was 83% (95% CI: 59-96%) and 99.0% (95% CI 98.1-99.5%), respectively (Table 1, Figure S3 panels A & B). The Bayesian population-weighted and test-adjusted seroprevalence for Kenya was 5.2% (95% CI 3.7-7.1%, Table 3 ) and the posterior sensitivity and specificity estimates were 82.5% (95% CI 69.6-91.2%) and 99.2 (95% CI 98.7-99.6%), respectively. In this anti-SARS-CoV-2 IgG seroprevalence study of blood donors in Kenya, the crude prevalence was 5.6% and the population-weighted test-adjusted seroprevalence was 5.2%.	./cache/cord-348342-iqq8kmn0.txt	./txt/cord-348342-iqq8kmn0.txt